These effects build gradually and may take several weeks to become noticeable
Kranc, K
CV safety is currently under investigation for tirzepatide in patients with obesity without diabetes (NCT05556512) and for cagrilintide/semaglutide with overweight and obesity with and without diabetes (NCT05669755)

Mechanism of Action Stimulates angiogenesis (formation of new blood vessels) Increases fibroblast activity and collagen synthesis Reduces pro-inflammatory cytokines and promotes anti-inflammatory cascades Enhances tendon-to-bone healing , muscle fiber regeneration, and gut lining repair Works through interaction with the nitric oxide system , aiding circulation and tissue oxygenation BPC157 promotes tendon and ligament healing, accelerates wound closure, and stabilizes vascular response after injury. Sikiric et al., Current Pharmaceutical Design Applications Joint pain, tendonitis, ligament tears Ulcers, IBS, leaky gut Muscle strain, post-surgical recovery Neural repair and recovery from nerve compression Post-cycle inflammation and tissue stress Delivery Administered via subcutaneous injection , near site of injury or systemically Can also be taken orally for GI-related issues (due to gastric stability) MK677 (Ibutamoren) Overview and How It Works MK677 (Ibutamoren) is an orally active growth hormone secretagogue that mimics the action of ghrelin to stimulate the release of growth hormone (GH) and IGF1

RFC1 -related ataxia is a mimic of early multiple system atrophy
Tesamorelin: The One That Targets Visceral Fat Tesamorelin is a growth hormone-releasing hormone analog that was originally approved by the FDA to reduce excess belly fat in patients with HIV-associated lipodystrophy